ABIOMED INC Form 8-K May 16, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

Date of Report: May 16, 2012

(Date of earliest event reported)

# ABIOMED, Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-20584 04-2743260

(State or other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number) 22 Cherry Hill Drive	Identification Number)
	Danvers, MA 01923	
(Address of Principal Executive Offices, including Zip Code)		
(978) 646-1400		
(Registrant s Telephone Number, including Area Code)		
Not Applicable		
(Former Name or Former Address, if Changed Since Last Report)		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:		
" Written communications pursuant to Rule 425	under the Securities Act (17 CFR 230.425	5)
" Soliciting material pursuant to Rule 14a-12 un	der the Exchange Act (17 CFR 240.14a-12	2)
" Pre-commencement communications pursuant	to Rule 14d-2(b) under the Exchange Act	(17 CFR 240.14d-2(b))
" Pre-commencement communications pursuant	to Rule 13e-4(c) under the Exchange Act	(17 CFR 240.13e-4(c)

#### Item 2.02 Results of Operations and Financial Condition.

On May 16, 2012 we issued a press release reporting our financial results for our fourth quarter and fiscal year ended March 31, 2012. A copy of the press release is set forth as exhibit 99.1 and is incorporated herein by reference. The information contained in this report shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Act of 1934, whether made before or after the date hereof and regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

# Item 9.01 Financial Statements and Exhibits. (d) Exhibits.

**Exhibit** Description

99.1 Press release dated May 16, 2012.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Abiomed, Inc.

By: /s/ Robert L. Bowen Robert L. Bowen Vice President and Chief Financial Officer

(Principal Accounting and Financial Officer)

Date: May 16, 2012

#### **Exhibit Index**

**Exhibit Number** 

**Description**Press release dated May 16, 2012. 99.1